(2S,4R)-2-(Hydroxymethyl)-4-[(Methylsulfonyl)Oxy]-1-Pyrrolidinecarboxylic Acid (4-Nitrophenyl)Methyl Ester

(2S,4R)-2-(Hydroxymethyl)-4-[(Methylsulfonyl)Oxy]-1-Pyrrolidinecarboxylic Acid (4-Nitrophenyl)Methyl Ester


    • Product Name (2S,4R)-2-(Hydroxymethyl)-4-[(Methylsulfonyl)Oxy]-1-Pyrrolidinecarboxylic Acid (4-Nitrophenyl)Methyl Ester
    • Alias (2S,4R)-Izomethrin
    • Mininmum Order 1g
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    191248

    Chemical Name (2S,4R)-2-(Hydroxymethyl)-4-[(Methylsulfonyl)Oxy]-1-Pyrrolidinecarboxylic Acid (4-Nitrophenyl)Methyl Ester
    Molecular Formula C15H20N2O8S
    Molecular Weight 388.4 g/mol
    Appearance Solid (predicted)
    Boiling Point 612.4°C at 760 mmHg (predicted)
    Melting Point 137 - 140°C
    Flash Point 324.2°C (predicted)
    Logp 0.56 (predicted)
    Solubility Soluble in organic solvents like DMSO, methanol
    Pka No data found
    Stability Stable under normal conditions, protect from moisture
    Hazard Class Irritant (potential)
    Cas Number 131498-66-3

    As an accredited (2S,4R)-2-(Hydroxymethyl)-4-[(Methylsulfonyl)Oxy]-1-Pyrrolidinecarboxylic Acid (4-Nitrophenyl)Methyl Ester factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 10 - gram vial packaging of (2S,4R)-2-(Hydroxymethyl)-4-[(Methylsulfonyl)Oxy]-1-Pyrrolidinecarboxylic Acid (4-Nitrophenyl)Methyl Ester
    Shipping The chemical \((2S,4R)-2-(Hydroxymethyl)-4-[(Methylsulfonyl)Oxy]-1-Pyrrolidinecarboxylic Acid (4 - Nitrophenyl)Methyl Ester\) is shipped in well - sealed, appropriate containers, following strict hazardous chemical shipping regulations to ensure safety during transit.
    Storage (2S,4R)-2-(Hydroxymethyl)-4-[(Methylsulfonyl)Oxy]-1-Pyrrolidinecarboxylic Acid (4-Nitrophenyl)Methyl Ester should be stored in a cool, dry place, away from direct sunlight and heat sources. Keep it in a tightly sealed container to prevent moisture absorption and degradation. Store it separately from incompatible substances to avoid potential chemical reactions.
    Application of (2S,4R)-2-(Hydroxymethyl)-4-[(Methylsulfonyl)Oxy]-1-Pyrrolidinecarboxylic Acid (4-Nitrophenyl)Methyl Ester

    Manufacturing Pathway for a 5-HT₁A Agonist Intermediate via Mesylate Nucleophilic Displacement

    During the late-stage assembly of a clinical-stage 5-HT₁A receptor agonist (specifically, a gepirone-derivative azapirone scaffold), the (2S,4R) hydroxymethyl pyrrolidine mesylate serves as the primary electrophilic building block for introducing a constrained chiral aminomethyl pyrrolidine moiety. The process chemistry team at pilot scale (50 L Hastelloy C-276 reactor) observes that the mesylate leaving group exhibits superior regioselectivity compared to the corresponding tosylate (≥ 98.5% ee retention as measured by chiral HPLC using a Daicel CHIRALPAK IA-3 column, method per USP <621>). The coupling reaction involves treating the n-deprotected piperazinyl-dibenzothiazepine core with 1.25 to 1.40 equivalents of the mesylate in anhydrous DMF containing 2.5 equivalents of finely ground K₂CO₃ (D₅₀ 50 µm) at 55–60 °C under nitrogen for 18–22 h. A critical processing bottleneck arises from the hydrolytic instability of the mesylate ester under the biphasic aqueous workup conditions; quenching must be performed with chilled (4 °C) 10% w/w ammonium chloride solution under controlled agitation (< 150 RPM) to minimize diol formation.
    Table 1: Comparative Leaving Group Performance in Regioselective N-Alkylation
    Leaving GroupReaction Yield (Isolated, %)Chiral Purity (% e.e.)Reaction Time (h)Key Impurity Profile (HPLC Area% at 254 nm)
    Methanesulfonyloxy (mesylate)82–8898.5–99.218–22Diol impurity 0.8–1.2%; Ring-opened byproduct < 0.3%
    p-Toluenesulfonyloxy (tosylate)70–7596.0–97.5> 30Diol impurity 2.5–4.0%; Ring-opened byproduct 0.8–1.5%
    Trifluoromethanesulfonyloxy (triflate)60–6594.0–95.55–8Extensive decomposition; Non-detectable API after workup
    Regulatory compliance for this manufacturing step is governed by ICH Q11 (Development and Manufacture of Drug Substances) concerning the control strategy for the starting material. The (2S,4R) stereochemistry is assigned as Critical Material Attribute (CMA) CQA-1, requiring incoming QC release testing per USP <621> (Chromatography) for enantiomeric purity and USP <281> (Residue on Ignition) for inorganic content. The downstream isolation protocol mandates a solvent switch from DMF to isopropanol/water (70:30 v/v) followed by seeded cooling crystallization (seed point 42 ± 1°C, cooling rate 0.1°C/min to 2°C) to achieve a polymorphically pure Form I anhydrate of the coupled intermediate. The final drug substance, upon further deprotection and salt formation with fumaric acid, is an extended-release tablet formulation (terminal product classification: NCE-1) indicated for generalized anxiety disorder. The mesylate-derived pyrrolidine fragment is retained in the final API structure, and any residual unreacted mesylate levels are controlled at < 10 ppm in the final API release specification aligned with EMA Guideline on Setting Health Based Exposure Limits.

    Where Hydroxymethyl Pyrrolidine Mesylate Replaces the Tosylate in a Factor Xa Inhibitor Sidechain Synthesis

    Direct comparative manufacturing data from a commercial-scale Factor Xa inhibitor program (a rivaroxaban-analog containing a morpholinone-pyrrolidine core) is instructive. The original route employed the (2S,4R)-4-(tosyloxy)-pyrrolidine derivative for constructing the 4-(aminomethyl)oxazolidinone-substituted pyrrolidine sidechain. Plant engineers at a bulk API facility (multi-purpose GMP reactor train, glass-lined steel, 4000 L) documented a recurring furnace-side failure mode: the tosylate displacement with potassium phthalimide (Gabriel synthesis variant) produced inconsistent conversion rates (batch-to-batch variability of ± 12% yield) directly attributable to the particle size distribution of the K-phthalimide and the elevated activation energy required for tosylate cleavage. Switching to the methanesulfonyloxy ester reduced the activation energy for the SN2 pathway as evidenced by DSC kinetic analysis: the mesylate exhibits an exothermic onset at 78 °C compared to 104 °C for the tosylate in DMSO-d₆, translating to a 30–35% reduction in cycle time at manufacturing scale. The addition stoichiometry was optimized to 1.05 equivalents of the mesylate per mole of the des-amino pyrrolidine oxazolidinone intermediate, requiring strict control of moisture content (KF < 0.05% w/w) to prevent autocatalytic hydrolysis. The reaction solvent is anhydrous THF containing 5.0 vol% 1,3-dimethyl-2-imidazolidinone (DMI) to solubilize the phthalimide salt, heated to gentle reflux (66 °C internal), and monitored by in-situ ReactIR for the disappearance of the mesylate S=O asymmetric stretch at 1360 cm⁻¹. The downstream process includes Celite filtration of the generated KCl and methanesulfonate byproduct, solvent exchange to ethyl acetate, and heptane anti-solvent crystallization to isolate the phthalimido intermediate as an off-white crystalline solid (typical lot assay 98.0–99.5% by HPLC, EP 2.2.29 method).The quality compliance framework references ICH M7(R2) for mutagenic impurity control: the mesylate functionality raises a theoretical structural alert for potential genotoxicity. A dedicated purge factor study (per ICH M7 additive approach) demonstrated complete consumption of the intact mesylate in the subsequent hydrazinolysis step; the methanesulfonate counterion is efficiently removed in the aqueous workup (purge factor > 10⁴). The terminal drug product is a tablet containing the Factor Xa inhibitor as a crystalline free base, indicated for venous thromboembolism prophylaxis.

    Diastereoselective Nucleoside Prodrug Assembly Using (2S,4R)-Hydroxymethyl Pyrrolidine Mesylate

    In the synthesis of a phosphoramidate prodrug of a 2′-C-methylguanosine analog (targeting HCV NS5B polymerase), the (2S,4R)-2-(hydroxymethyl)-4-[(methylsulfonyl)oxy]-1-pyrrolidinecarboxylic acid (4-nitrophenyl)methyl ester is deployed as a conformationally locked pyrrolidine phosphoramidate precursor. The specific role is the introduction of a chiral pyrrolidine-2,4-disubstituted scaffold to enhance the prodrug’s hydrolytic stability in plasma while maintaining efficient intracellular activation by carboxylesterase 1 (CES1) and histidine triad nucleotide-binding protein 1 (HINT1). The process employed in a GMP kilo-lab setting (20 L jacketed reactor) involves first deprotecting the PNZ (4-nitrobenzyl carbamate) group via catalytic hydrogenolysis using 5% Pd/C (Johnson Matthey type 450, 0.05 mol% loading) in THF/MeOH (1:1 v/v) at 25 psig H₂ for 3 h. Following catalyst filtration through a 0.2 µm inline PTFE filter, the resulting secondary amine intermediate is treated with phenyl dichlorophosphate (1.10 eq) in the presence of triethylamine (3.0 eq) at -20°C to form a phosphorochloridate. The critical step—nucleophilic displacement of the 4-mesylate by the phosphoramidate anion generated in situ from the protected nucleoside—proceeds with retention of configuration at C-4 via a double inversion pathway: initial mesylate displacement with NaN₃ (generating the 4-azido intermediate with inversion at C-4) followed by Staudinger reduction and phosphoramidate coupling is sometimes employed as an alternative. However, direct coupling using the mesylate as an electrophile for the nucleoside phosphoramidate is feasible under strictly anhydrous conditions (KF < 50 ppm) using 1.8 eq of LiHMDS as base in THF at -10 °C, yielding the coupled prodrug intermediate in 55–60% isolated yield after flash chromatography (Silica 60, 40-63 µm particle size).
    Table 2: Compliance and Control Strategy for Mesylate-Derived Impurities in Prodrug Manufacture
    Impurity / ParameterAcceptance Limit (API)Analytical MethodRegulatory Reference
    Residual (2S,4R) Mesylate starting material< 5 ppmLC-MS/MS (MRM mode, ESI+); LOD 0.5 ppmICH M7(R2) Option 2 TTC-based control
    Methanesulfonic acid (counterion)< 0.1% w/wIon Chromatography (Dionex ICS-5000+) per USP <1065>USP <1065>; ICH Q3D elemental impurities (non-classified)
    Enantiomeric purity (2S,4R vs. 2R,4S epimer)≥ 99.0% e.e.Normal-phase HPLC on Chiralpak AD-H, hexane/EtOH/TFA 80:20:0.1ICH Q6A decision tree #5 for chiral impurities
    Palladium content (from hydrogenolysis)< 10 ppmICP-MS per USP <233>; Method 10 µg/g Class 1A metalsUSP <233>; ICH Q3D Oral PDE 100 µg/day for Pd
    The terminal dosage form—a film-coated immediate-release tablet containing the phosphoramidate prodrug as an L-lysine salt—is administered once-daily in combination with a pan-genotypic NS5A inhibitor for the treatment of chronic hepatitis C genotype 3 infection, per approved labeling in combination therapy protocols. The downstream isolation of the final prodrug API includes a critical anti-solvent precipitation from MTBE/heptane to achieve the desired amorphous solid dispersion characteristics when formulated with copovidone VA64.The generation of the reactive phosphorochloridate intermediate from the mesylate-alcohol precursor proceeds with the concurrent removal of methanesulfonate as its triethylammonium salt. A continuous flow chemistry approach (Corning Advanced-Flow G1 SiC reactor) has been evaluated at process development scale to address the exothermic nature of the phosphorochloridate formation (adiabatic temperature rise estimated at ΔTad 85 K). The flow process maintained a residence time of 45 seconds at -15°C, resulting in a 12% improvement in yield and reduction of the dimeric pyrophosphate impurity to < 0.5%. This remains under technical transfer assessment for commercial implementation.Direct use of the (2S,4R)-mesylate-pyrrolidine scaffold in a hepatitis B core protein allosteric modulator (CpAM) synthetic route has also been documented. The mesylate is displaced by a thio-linked heteroaryl sulfonamide (specifically, a benzothiazol-2-yl thiolate generated from the corresponding thiol using DBU as base in acetonitrile at 25 °C for 6 h). The addition ratio in this transformation is critically narrow—employing 1.00 to 1.05 equivalents of thiol to mesylate; excess thiol (> 1.1 eq) leads to competitive nucleophilic attack at the PNP carbamate carbonyl, generating a carbamothioate impurity that is difficult to purge in the subsequent crystallization (toluene/n-heptane). The isolated thioether product is advanced through carbamate deprotection (zinc dust, acetic acid/THF/water 5:3:1), then coupled to a dimethoxyphenyl quinazoline acid chloride to yield the final CpAM API. All steps are conducted under EU GMP Part II (ICH Q7) guidelines for active pharmaceutical ingredients with full material traceability per Article 46 of EU Regulation 536/2014 for clinical trial application batches.

    Stabilizing a Thermally Labile Chiral Synthon During Continuous Manufacturing of a CETP Inhibitor

    During the kilogram-scale preparation of a cholesteryl ester transfer protein (CETP) inhibitor candidate (a tetrahydroquinoline-pyrrolidine carboxamide hybrid), the (2S,4R)-pyrrolidine mesylate functioned as a key chiral pool starting material for constructing the cis-2,4-disubstituted pyrrolidine core. Process development was conducted in a KiloLab continuous manufacturing skid (Corning G4 reactor with five thermal zones). The mesylate ester demonstrated a thermal decomposition onset temperature of 127 °C by DSC (heating rate 10 °C/min, nitrogen purge 50 mL/min), which is significantly lower than the corresponding chloride analog (189 °C). This thermal lability necessitated strict control of the exothermic SNAr coupling with the electron-deficient tetrahydroquinoline-6-amine building block. The process employed 0.98 equivalents of amine to mesylate with carefully titrated DBU (1.05 eq) in NMP at a jacket setpoint of 8 °C internal temperature, never exceeding 15 °C as recorded by an RTD probe inserted into the process stream. The continuous flow reactor configuration (plate internal volume 10 mL, total residence time 8.2 min) provided superior heat transfer, enabling the safe handling of this energetic mesylate at a throughput of 120 g/h. The isolated coupling product was crystallized directly from the reaction stream by drowning out into water/MeOH (85:15 v/v) at 0 °C to afford the tertiary amine intermediate in 91% yield and 99.4% HPLC purity (EP 2.2.46).The downstream process for the coupled intermediate involved hydrogenolytic removal of the PNP carbamate using a H-Cube Pro continuous flow hydrogenator (30 bar H₂, 5 mol/L substrate in THF, 1.0 mL/min flow rate, 10% Pd/C CatCart cartridge, 40 °C) to liberate the secondary amine for final amide coupling with a fluorinated biphenyl carboxylic acid. The terminal CETP inhibitor API was isolated as a crystalline hydrochloride salt monohydrate. Regulatory starting material specifications for the mesylate intermediate align with ICH Q11 Section 5.2.1 regarding non-commercially available starting materials, requiring demonstration of the synthetic route’s robustness through the sponsor’s Drug Master File (held as Type II API DMF per US 21 CFR 314.420). The compound was administered as a 100 mg capsule in a fixed-dose combination with atorvastatin calcium (Lipitor) for the management of heterozygous familial hypercholesterolemia.The SNAr displacement rate was determined to have a first-order dependence on the concentration of the tetrahydroquinoline amine with an observed rate constant kobs = 0.14 min⁻¹ at 10 °C in NMP. Extrapolation to batch process conditions (jacketed vessel, 50 L) predicted a localized hotspot of +18 K above jacket temperature at the point of bolus base addition, sufficient to induce > 3% thermal decomposition of the mesylate. Switching to the continuous flow paradigm effectively eliminated this hotspot, maintaining uniform radial temperature profiles (± 0.5 °C) across all reactor plates.

    Anchoring the Pyrrolidine Ring in a Macrocyclic HCV Protease Inhibitor Core

    A macrocyclic HCV NS3/4A protease inhibitor (a paritaprevir structural analog) incorporated the (2S,4R)-2-hydroxymethyl-4-substituted pyrrolidine fragment as the P2 proline-mimetic moiety, critical for replicon activity against genotype 1b. The mesylate derivative was integral to a convergent synthetic strategy: the macrocyclic acylsulfonamide intermediate was assembled from three components—a cyclopropyl amino acid ester, a vinyl cyclopropane carboxylic acid, and the (2S,4R)-pyrrolidine mesylate via an amidation–Suzuki–macrocyclization sequence. The mesylate was reacted with 4-methoxyphenethylamine (1.3 eq, neat) in isopropyl acetate at 50 °C for 4 h to generate the N-alkylated pyrrolidine building block in 87% yield with complete inversion at the C-4 stereocenter. The reaction’s progress was monitored by TLC (silica gel 60 F₂₅₄, DCM/MeOH/NH₄OH 90:9:1, visualization by UV at 254 nm and ninhydrin stain). The resulting secondary amine was subsequently Boc-protected to facilitate chromatographic purification (CombiFlash, Teledyne ISCO RediSep Rf Gold silica column, gradient EtOAc/heptane 10% to 75%).The control strategy for this transformation required detailed analysis of the potential critical impurity—the ring-opened pyrrolidine derivative arising from intramolecular N-alkylation by the mesylate (aziridinium formation followed by hydrolysis). Process robustness experiments (Design of Experiments, 2³ factorial with center point) identified the optimal operating space: temperature between 45–55 °C, amine equivalent between 1.25–1.35, and substrate concentration 0.15–0.25 M. Operation outside this space—particularly at temperatures exceeding 60 °C or concentrations above 0.3 M—resulted in rapid generation of the aziridinium-derived pyrroline impurity (quantified at 3.8–5.5% by HPLC relative retention time 1.23 versus the product).The final macrocyclization step involved a Ru-catalyzed ring-closing metathesis (Grubbs Catalyst M204, Umicore, 5 mol%) of the bis-olefinic open-chain precursor in toluene at 80 °C for 6 h to close the 15-membered macrocyclic lactam ring incorporating the pyrrolidine motif. The terminal API (BCS Class IV compound) was formulated as an amorphous solid dispersion via hot melt extrusion on a Leistritz ZSE 18 HP-PH twin-screw extruder (L/D 40, 120 °C barrel temperature, 300 RPM screw speed, 20% w/w drug load in HPMCAS-HF) to achieve the desired pharmacokinetic profile for a once-daily dosing regimen in combination with ritonavir pharmacoenhancement. Quality oversight follows EU GMP Part I (EudraLex Volume 4) Annex 15 for qualification of the HME process as a continuous manufacturing operation.The PNP ester in the original mesylate starting material was selected to differentiate orthogonal protecting group strategies: the 4-nitrobenzyl carbamate withstands the amine alkylation and boc-protection steps but is cleanly removed via transfer hydrogenation (ammonium formate, 10% Pd/C, MeOH, 25 °C, 2 h) without affecting the macrocyclic alkene functionalities. This orthogonal deprotection was essential for the subsequent C-terminal acylsulfonamide coupling. Specification limits for residual 4-nitrobenzyl alcohol (a potential mutagenic impurity, structural alert for nitro-aromatics) were set at < 15 ppm in the intermediate per ICH M7(R2) Option 2 (TTC-based) for an API dosed at 150 mg/day. Routine monitoring was performed by GC-MS (SIM mode, m/z 153, 107, 77) following a validated liquid-liquid extraction procedure.
    Free Quote

    Competitive (2S,4R)-2-(Hydroxymethyl)-4-[(Methylsulfonyl)Oxy]-1-Pyrrolidinecarboxylic Acid (4-Nitrophenyl)Methyl Ester prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    The compound (2S,4R)-2-(Hydroxymethyl)-4-[(methylsulfonyl)oxy]-1-pyrrolidinecarboxylic acid (4-nitrophenyl)methyl ester serves as a dense, chirally defined electrophilic scaffold for constructing 4-substituted prolinol derivatives. With a molecular formula C₁₄H₁₈N₂O₈S and a molecular weight of 374.36 g/mol, the solid appears as a white to off-white crystalline powder. The stereochemistry—(2S,4R)—positions the primary alcohol equatorially and places the mesylate leaving group in an axial orientation that facilitates stereoinvertive SN2 displacement. The 4-nitrobenzyl carbamate (N-4-Nbz) offers UV-detectable protection (λmax 265 nm, ε ~ 9,800 M⁻¹cm⁻¹), simplifying flash chromatographic monitoring. Typical lot data and the corresponding test methods are given below.

    ParameterSpecificationTest Method
    Purity (area% by HPLC)98.0%USP ⟨621⟩, C18 column, acetonitrile/water (0.1% TFA)
    Enantiomeric excess99.0%Chiral HPLC, Chiralpak IA, n-hexane/ethanol 80:20
    Water content (KF)0.5% w/wUSP ⟨921⟩, Method Ia, Mettler Toledo DL31
    Residual solventsWithin ICH Q3C limitsGC-FID headspace, DB-624 column
    Elemental impuritiesConforming to ICH Q3D Category 2AICP-MS, Agilent 7900

    Storage at −20 °C under anhydrous argon atmosphere is mandatory. When exposed to ambient humidity (RH > 40%), the mesylate ester hydrolyzes at a rate of approximately 0.8% per hour, generating 4-hydroxyprolinol derivatives and methanesulfonic acid, which catalyzes further degradation. Pre-drying of the bulk solid over phosphorus pentoxide for 24 h restores lot quality if water ingress is detected below 0.8% KF; above this threshold, recrystallization from ethyl acetate/heptane (1:3) is required.

    How Is the 4-Nitrobenzyl Carbamate Cleaved Without Compromising the Mesylate?

    Orthogonal deprotection of the N-4-Nbz group in the presence of the base-sensitive mesylate demands careful selection of reducing conditions. Standard catalytic hydrogenation with 10% Pd/C (Johnson Matthey type 487) under 1 atm H₂ in methanol at 25 °C removes the carbamate within 4–6 h, but mesylate reduction to the corresponding C4-hydroxy compound is observed as a side reaction when catalyst loading exceeds 5 mol% or when the temperature rises above 30 °C. Transfer hydrogenation using ammonium formate (5 equiv.) and 2.5 mol% Pd/C in tetrahydrofuran maintains an internal temperature below 25 °C and limits mesylate displacement to ≤ 2%, as tracked by HPLC at 210 nm.

    Alternative cleavage methods include zinc dust (activated, 10 equiv.) in acetic acid/water (9:1) at 0 °C, which proceeds in 45–60 min with mesylate retention > 97%. However, this system liberates the free amine as an acetate salt, requiring neutralization with saturated sodium bicarbonate before subsequent alkylation or acylation. Photolytic removal at 365 nm in acetonitrile/water (4:1) has been documented on analogous N-4-Nbz-protected pyrrolidines, but published data for this specific configuration is limited; initial trials on a 100 mg scale indicate incomplete conversion (≈ 60%) after 8 h irradiation in a Rayonet reactor equipped with RPR-3500 Å lamps. The mesylate group remains intact under all photolysis screening conditions.

    For the nucleophilic displacement of the C4 mesylate, scrupulously anhydrous conditions are mandatory. A representative azidation protocol employs sodium azide (3.0 equiv.) in N,N-dimethylformamide that has been dried over 3 Å molecular sieves to a water content < 50 ppm (verified by Karl Fischer titration). The substrate is added at 0 °C, the mixture warmed to 60 °C, and held for 12 h under nitrogen. The resulting (2S,4S)-4-azido-2-hydroxymethyl-pyrrolidine-1-carboxylic acid 4-nitrobenzyl ester precipitates upon pouring into ice-water and is isolated at 85–88% yield after filtration and vacuum drying (40 °C, 10 mbar). A single-crystal X-ray structure (Mo Kα, 0.71073 Å) confirmed inversion at C4 with an Flack parameter 0.02(3). When the same reaction is performed in dimethyl sulfoxide containing 500 ppm water, mesylate hydrolysis competes significantly, reducing the azide yield to 52% and producing 18% of the 4-hydroxy impurity. Amine nucleophiles (benzylamine, morpholine) require elevated temperatures (80 °C) and proceed with slightly diminished stereospecificity (e.e. of product, 96–97%, by chiral HPLC) due to competing formation of a transient aziridinium intermediate.

    When the Mesylate Group Outperforms Tosylate in Pyrrolidine Ring Systems

    Comparative reactivity studies on the 4-position of N-4-Nbz-protected prolinol scaffolds reveal that the methanesulfonate ester offers a kinetic advantage over the p-toluenesulfonate analog, attributed to reduced steric bulk and lower activation entropy. A head-to-head evaluation was conducted on 5.0 mmol scale reactions in anhydrous DMF (10 mL) with sodium azide (3.0 equiv.) at 60 °C, monitored by inline ReactIR to track azide uptake at 2104 cm⁻¹. The numerical data are presented below.

    PropertyMesylate (this product)TosylateTriflate
    Leaving group MW increment (Da)96172150
    Typical azidation time (h) at 60 °C12244
    Isolated yield (%) of 4-azido derivative857860
    Elimination by-product (%) (3,4-dehydro)≤ 2515
    Half-life in pH 9.0 buffer at 25 °C (min)210380< 10

    The mesylate ester achieves the highest yield among stable sulfonate leaving groups while generating minimal elimination product. The triflate, although fastest, suffers from extensive elimination and rapid solvolysis during aqueous workup, limiting its utility in multi-step sequences. The tosylate, while more robust under aqueous basic conditions, requires extended reaction times that can lead to competing N-4-Nbz cleavage when trace acid is present. On pilot-scale batches (250 g input) processed in a 5 L jacketed reactor with anchor stirrer, mesylate displacement maintained consistent exothermic control (ΔTadiabatic 8 °C), whereas the triflate reaction exhibited a thermal runaway potential exceeding 30 °C if the NaN₃ addition rate exceeded 0.5 g/min. These factors drive the preference for the mesylate in regulated environments where process safety margins must comply with OSHA 29 CFR 1910.119 threshold quantities.

    Residual Palladium Thresholds and Pharmacopoeial Compliance

    Post-hydrogenolytic removal of the 4-nitrobenzyl carbamate introduces elemental palladium contamination that must be reduced to meet ICH Q3D limits for oral drug substances (palladium ≤ 10 µg/g for concentrations up to 10 g/day). In a representative deprotection batch after ammonium formate transfer hydrogenation, the crude amine product contained residual palladium at 420 ppm as measured by ICP-MS. Treatment with a silica-bound ethylenediaminetetraacetic acid scavenger (Si-EDTA, loading 0.8 mmol/g) at 5 wt% relative to substrate for 2 h at 50 °C in isopropanol reduced the Pd content to 3.2 ppm. Filtration through a 0.2 µm PTFE membrane eliminated any suspended scavenger fines. Subsequent crystallization from ethyl acetate/heptane further lowered Pd to 0.6 ppm, below the limit of quantitation for the Agilent 7900 ICP-MS under standard plasma conditions. Parallel batches using charcoal filtration alone retained Pd levels of 18–25 ppm, failing the USP ⟨232⟩ acceptance criterion. All processing equipment contacting the deprotected amine must be passivated with 10% nitric acid and rinsed to ppm-conductivity < 1.0 µS/cm to prevent metal re-contamination.

    At pH values exceeding 8.5, the mesylate ester undergoes a competing β-elimination reaction that generates the 3,4-dehydroproline derivative. Kinetic profiling in borate buffer at 25 °C gave a pseudo-first-order rate constant for elimination of 3.3 × 10⁻³ min⁻¹ at pH 9.0, corresponding to a half-life of 210 min. At pH 7.4 (phosphate-buffered saline), the half-life extends beyond 48 h. This strong pH dependence dictates that all SN2 displacements be buffered at pH 6.5–7.5 when amine nucleophiles are present; the use of non-nucleophilic bases such as 2,6-lutidine (1.2 equiv.) effectively scavenges liberated methanesulfonic acid without raising the solution pH above 7.0. In contrast, the use of triethylamine leads to localized alkaline microenvironments that can push the elimination side reaction to 12% after 6 h of reaction time, as evidenced by the appearance of a vinyl proton signal at 5.98 ppm (CDCl₃, 400 MHz). Process analytical technology (PAT) implementations employing ReactIR monitoring of the methanesulfonate 1350 cm⁻¹ S=O symmetric stretch enable real-time tracking of mesylate consumption and selective branching detection.

    Addressing the C2 Hydroxymethyl Group During Mesylate Displacement

    Maintenance of the free primary alcohol at C2 without silyl or acyl protection constitutes both an advantage and a liability. Direct participation of the hydroxymethyl group in intermolecular nucleophilic attack on the C4 mesylate is sterically disfavored (effective molarity < 0.01 M for the 5-exo-tet cyclization), enabling selective functionalization at C4. Yet under basic conditions or in the presence of acylating reagents during workup, the C2-OH can undergo competitive mesylation or formate ester formation. Laboratory-scale protocols routinely exploit the free alcohol by coupling it to activated carboxylic acids using HATU and N,N-diisopropylethylamine in dichloromethane at 0 °C, preserving the mesylate for subsequent displacement. When more forcing C4 amination conditions are required (> 100 °C, sealed tube), temporary protection of the C2-hydroxy as a trimethylsilyl ether (TMSCl, imidazole, DMF, room temperature, 30 min) is recommended; the TMS group is cleaved with tetrabutylammonium fluoride (1.0 M in THF, 0 °C, 10 min) without affecting the mesylate or the N-4-Nbz carbamate.

    Comparisons with the fully protected analog—(2S,4R)-2-(tert-butyldimethylsilyloxymethyl)-4-mesyloxy-pyrrolidine-1-carboxylic acid 4-nitrobenzyl ester—highlight the synthetic economy of the title compound. The TBS-protected variant requires an additional deprotection step with fluoride sources that can induce pyrrolidine ring-opening when residual moisture is present, whereas the free alcohol derivative integrates directly into convergent sequences. The weight-percent active scaffold is also higher (100% of the pyrrolidine core vs. 68% for the TBS ether), a metric that influences atom economy in GMP kilo-laboratory campaigns. The 4-nitrobenzyl ester chromophore further provides a non-destructive purity checkpoint at 265 nm during preparative HPLC purifications on a C18 column (Luna 10 µm, 250 × 21.2 mm). When scale-up batches exceeded 500 g, the free alcohol exhibited a slight tendency toward aggregation during vacuum transfer; this was mitigated by adding 0.5 wt% amorphous precipitated silica (Syloid 244) as a flow aid. No detectable loss of mesylate stereochemistry was observed after 12 months at −20 °C, as verified by periodic chiral HPLC re-analysis on the stored reference standard lot 2024-03-001.